Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459843 | 0.86 | PIK3CD (0.61) | ATMPIK3CD | |
| SCHEMBL10469223 | 0.86 | PIK3CD (0.61) | ATMPIK3CD | |
| SCHEMBL9028110 | 0.86 | PIK3CD (0.61) | ATMPIK3CD | |
| SCHEMBL9028119 | 0.86 | PIK3CD (0.61) | ATMPIK3CD | |
| SCHEMBL13862237 | 0.85 | ATM (0.54) | ATMPIK3CDMMP2MMP9MMP8 | |
| SCHEMBL9310210 | 0.85 | ATM (0.50) | ATMPIK3CDMMP2MMP9MMP8 | |
| SCHEMBL9309228 | 0.84 | ATM (0.46) | ATMPIK3CDMMP2MMP9MMP8 | |
| SCHEMBL4424510 | 0.84 | PIK3CD (0.52) | ATMPIK3CDFFAR2 | |
| SCHEMBL9310446 | 0.81 | ATM (0.50) | ATMPIK3CDMMP2MMP9MMP8 | |
| SCHEMBL9308182 | 0.81 | ATM (0.50) | ATMPIK3CDMMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | ATM 4443/4885PIK3CD 1999/4885MMP2 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.